Acadian Asset Management LLC Fate Therapeutics Inc Transaction History

Acadian Asset Management LLC

  • $32.2 Billion
  • Q3 2024

A detailed history of Acadian Asset Management LLC transactions in Fate Therapeutics Inc stock. As of the latest transaction made, Acadian Asset Management LLC holds 1,602,120 shares of FATE stock, worth $3.67 Million. This represents 0.02% of its overall portfolio holdings.

Number of Shares
1,602,120
Previous 2,008,862 20.25%
Holding current value
$3.67 Million
Previous $6.59 Million 14.88%
% of portfolio
0.02%
Previous 0.02%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024
SELL
$3.12 - $5.57 $1.27 Million - $2.27 Million
-406,742 Reduced 20.25%
1,602,120 $5.61 Million
Q2 2024

Aug 06, 2024
BUY
$3.26 - $7.08 $960,845 - $2.09 Million
294,738 Added 17.19%
2,008,862 $6.59 Million
Q1 2024

May 10, 2024
SELL
$3.54 - $8.35 $2.01 Million - $4.73 Million
-567,047 Reduced 24.86%
1,714,124 $12.6 Million
Q4 2023

Feb 13, 2024
BUY
$1.65 - $3.94 $217,097 - $518,401
131,574 Added 6.12%
2,281,171 $8.53 Million
Q3 2023

Nov 13, 2023
BUY
$2.02 - $5.04 $2.5 Million - $6.23 Million
1,236,680 Added 135.46%
2,149,597 $4.56 Million
Q2 2023

Aug 07, 2023
BUY
$4.76 - $6.59 $4.35 Million - $6.02 Million
912,917 New
912,917 $4.34 Million
Q2 2018

Jul 24, 2018
SELL
$9.16 - $13.48 $94,778 - $139,477
-10,347 Closed
0 $0
Q1 2018

Apr 12, 2018
BUY
$6.3 - $13.77 $65,186 - $142,478
10,347 New
10,347 $101,000

Others Institutions Holding FATE

# of Institutions
175
Shares Held
115M
Call Options Held
53.7K
Put Options Held
9K
View Full List

About FATE THERAPEUTICS INC

FATE Quotes by TradingView
  • Ticker FATE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,000,304
  • Market Cap $222M
  • Description
  • Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. Its NK- and T-cell immuno-oncology programs under development include FT516 for the treatment of acute myeloid leukemia (AML) B-cell lymphoma, and advanced solid tumor; FT596 to treat B-cell...
More about FATE
Track This Portfolio

Track Acadian Asset Management LLC Portfolio

Follow Acadian Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Acadian Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Acadian Asset Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email